NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)

NX Development Corp. (NXDC) has reached a significant milestone. Following the FDA's Orphan Designation for diagnostic management of ovarian, fallopian tube, and primary peritoneal cancer, the first patient was enrolled in the OVA-302 study. The surgery, utilizing Gleolan, was successfully completed.

Salvatore DeSena, MD, CEO of NX Development Corp., expressed excitement at the progress. He noted the quick achievement in their ovarian development program and the scheduling of the second patient for surgery. DeSena congratulated the NXDC team and external investigators.

Dr. Ulrich Kosciessa, Chairman of the Board of NXDC, highlighted the group's pride in developing Gleolan for fluorescence-guided surgery in oncological diseases. With the initiation of the OVA-302 study in the US, they plan to expand into Europe, Japan, and other indications.

Gleolan is an optical imaging agent used in patients with glioma for visualizing malignant tissue during surgery. It has gained clinical recognition for this application.